{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:17:24Z","timestamp":1794374244026,"version":"4.9.0"},"reference-count":38,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"12","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2021,4,20]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Patients with the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL) historically showed inferior survival with standard rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Phase II studies demonstrated that adding the immunomodulatory agent lenalidomide to R-CHOP improved outcomes in ABC-type DLBCL. The goal of the global, phase III ROBUST study was to compare lenalidomide plus R-CHOP (R2-CHOP) with placebo\/R-CHOP in previously untreated, ABC-type DLBCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Histology and cell-of-origin type were prospectively analyzed by central pathology prior to random assignment and study treatment. Patients with ABC-DLBCL received lenalidomide oral 15 mg\/d, days 1-14\/21 plus standard R-CHOP21 versus placebo\/R-CHOP21 for six cycles. The primary end point was progression-free survival (PFS) per independent central radiology review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>A total of 570 patients with ABC-DLBCL (n = 285 per arm) were stratified by International Prognostic Index score, age, and bulky disease, and randomly assigned to R2-CHOP or placebo\/R-CHOP. Baseline demographics were similar between arms. Most patients completed six cycles of treatment: 74% R2-CHOP and 84% placebo\/R-CHOP. The most common grade 3\/4 adverse events for R2-CHOP versus placebo\/R-CHOP were neutropenia (60% v 48%), anemia (22% v 14%), thrombocytopenia (17% v 11%), and leukopenia (14% v 15%). The primary end point of PFS was not met, with a hazard ratio of 0.85 (95% CI, 0.63 to 1.14) and P = .29; median PFS has not been reached for either arm. PFS trends favoring R2-CHOP over placebo\/R-CHOP were seen in patients with higher-risk disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>ROBUST is the first DLBCL phase III study to integrate biomarker-driven identification of eligible ABC patients. Although the ROBUST trial did not meet the primary end point of PFS in all patients, the safety profile of R2-CHOP was consistent with individual treatments with no new safety signals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.20.01366","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T15:59:59Z","timestamp":1614095999000},"page":"1317-1328","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":270,"title":["ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma"],"prefix":"10.1200","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6955-9393","authenticated-orcid":false,"given":"Grzegorz S.","family":"Nowakowski","sequence":"first","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2977-0098","authenticated-orcid":false,"given":"Annalisa","family":"Chiappella","sequence":"additional","affiliation":[{"name":"Division of Hematology, A.O.U. Citt\u00e0 della Salute e della Scienza Hospital and University, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy D.","family":"Gascoyne","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0435-5947","authenticated-orcid":false,"given":"David W.","family":"Scott","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer, British Columbia Cancer, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"Maria Sklodowska-Curie Institute\u2014Oncology Centre, Cracow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1326-1918","authenticated-orcid":false,"given":"Muhit","family":"\u00d6zcan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Hong","sequence":"additional","affiliation":[{"name":"Cancer Hospital, Fudan University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Beijing Cancer Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Medical School of Zhejiang University, First Hospital of Zhejiang Province, Hangzhou, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Belada","sequence":"additional","affiliation":[{"name":"Fourth Department of Internal Medicine-Hematology, Charles University Hospital and Faculty of Medicine, Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8229-1208","authenticated-orcid":false,"given":"Juan Miguel","family":"Bergua","sequence":"additional","affiliation":[{"name":"Servicio de Hematologia, Hospital Universitario San Pedro de Alc\u00e1ntara, C\u00e1ceres, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2831-623X","authenticated-orcid":false,"given":"Francesco","family":"Piazza","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of Padova and Azienda Ospedaliera di Padova, Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"M\u00f3cikova","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Haematology, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Lia","family":"Molinari","sequence":"additional","affiliation":[{"name":"UO Ematologia, Ospedale Degli Infermi, Rimini, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Cavallo","sequence":"additional","affiliation":[{"name":"AOU Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tani","sequence":"additional","affiliation":[{"name":"U.O. Ematologia, Dipartimento Oncologia e Ematologia, Ospedale Santa Maria delle Croci, Ravenna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8588-8955","authenticated-orcid":false,"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Izutsu","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Medicine and Biosystemic Science, Kyushu University Faculty of Medicine, Fukuoka City, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron","family":"Czuczman","sequence":"additional","affiliation":[{"name":"Clinical Research and Development, Celgene Corporation, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hersey","sequence":"additional","affiliation":[{"name":"Translational Development, Precision Medicine and Companion Diagnostics, Celgene Corporation, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Kilcoyne","sequence":"additional","affiliation":[{"name":"Clinical Research and Development, Celgene Corporation, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Russo","sequence":"additional","affiliation":[{"name":"Clinical Research and Development, Celgene Corporation, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Hudak","sequence":"additional","affiliation":[{"name":"Clinical Research and Development, Celgene Corporation, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingshan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical Research and Development, Celgene Corporation, Summit, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Wade","sequence":"additional","affiliation":[{"name":"Department of Statistical Programming, Celgene Corporation, Overland Park, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-6500","authenticated-orcid":false,"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[{"name":"Division of Hematology, A.O.U. Citt\u00e0 della Salute e della Scienza Hospital and University, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2780"},{"key":"b2","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv304"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00014"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30935-5"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.2784"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02403"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.3402"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1038\/35000501"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa012914"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-536433"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1545"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1732008100"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802885"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.2874"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-628669"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12172"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3429"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq626"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26135"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70191-3"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.5714"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0145-9"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq195"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3488"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"b30","volume-title":"Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics","author":"Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research (US)","year":"2007"},{"key":"b31","doi-asserted-by":"publisher","DOI":"10.1002\/hon.6_2629"},{"key":"b32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"b33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2493"},{"key":"b34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0016-8"},{"key":"b35","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.220475"},{"key":"b36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.5198"},{"key":"b37","first-page":"abstract 419","volume":"130","author":"Szafer-Glusman E","year":"2017","journal-title":"Blood"},{"key":"b38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2011.02.001"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.20.01366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T05:52:25Z","timestamp":1653803545000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.20.01366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,20]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,4,20]]}},"alternative-id":["10.1200\/JCO.20.01366"],"URL":"https:\/\/doi.org\/10.1200\/jco.20.01366","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,20]]},"assertion":[{"value":"2020-05-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}